Cargando…

PB2292: DEVELOPMENT OF CARDIOTOXICITY NEGATIVELY IMPACTS IN OVERALL SURVIVAL IN PATIENTS WITH LYMPHOMA TREATED WITH FIRST-LINE ANTHRACYCLINES

Detalles Bibliográficos
Autores principales:	Garcia, Alberto Lopez, Macia, Ester, Gomez-Talavera, Sandra, Castillo-Bazan, Eva, Morillo, Daniel, Ibañez, Borja, Cordoba, Raul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429679/ http://dx.doi.org/10.1097/01.HS9.0000975896.32740.f9

Ejemplares similares

PB2292: AMSAN VARIANT OF GUILLAIN BARRE SYNDROME COMPLICATING THE RECOVERY PHASE OF COVID-19 RELATED DISEASE
por: Haidary, A. M., et al.
Publicado: (2022)

PB2126: R-CPOP AS FIRST LINE TREATMENT FOR DLBCL PATIENTS WITH SIGNIFICANT REDUCED LVEF OR HIGH RISK OF ANTHRACYCLINE INDUCED CARDIOTOXICITY
por: Lorenz, K., et al.
Publicado: (2022)

PB2325: VALIDATION OF THE TRAIL SCORE TO PREDICT TOXICITY IN PATIENTS WITH DLBCL RECEIVING R-CHOP-LIKE THERAPY
por: Caballero, Juan Carlos, et al.
Publicado: (2023)

PB2194: ISCHEMIC STROKE IN PATIENTS WITH THROMBOCYTOPENIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Pérez Raya, M., et al.
Publicado: (2022)

PB2261: DECREASE IN NEUTROPHIL-LYMPHOCYTE RATIO IMPACTS OVERALL SURVIVAL OF ADULT PATIENTS WITH HODGKIN LYMPHOMA AFTER ANTI-PD1 TREATMENT
por: Varelas, Christos, et al.
Publicado: (2023)

PB2266: TRIAL IN PROGRESS: PHASE 3 TRIAL OF ODRONEXTAMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND MARGINAL ZONE LYMPHOMA (OLYMPIA-5)
por: Vitolo, Umberto, et al.
Publicado: (2023)

PB1935: CARDIOTOXICITY AND SAFETY OF BRUTON’S TYROSINE KINASE INHIBITORS: A REVIEW OF REAL-WORLD OBSERVATIONAL EVIDENCE
por: Balijepalli, Chakrapani, et al.
Publicado: (2023)

PB2164: PROGNOSTIC IMPACT OF ONCOGENE DEK IN DIFFUSE LARGE B-CELL LYMPHOMA
por: Alonso Alonso, R., et al.
Publicado: (2022)

The Quest for an Early Marker of Anthracycline-Induced Cardiotoxicity
por: Ibanez, Borja, et al.
Publicado: (2022)

PB2699: CONSENSUS FROM AN EXPERT PANEL ON THE CURRENT MANAGEMENT OF SECONDARY IMMUNODEFICIENCY IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES IN SPAIN
por: Boqué, Concepción, et al.
Publicado: (2023)

PB1870: FACTORS ASSOCIATED WITH OVERALL SURVIVAL IN ACUTE MYELOID LEUKEMIA: RENEHOC REGISTRY STUDY.
por: Sossa, Claudia Lucía, et al.
Publicado: (2023)

PB2119: REDUCED OVERALL SURVIVAL OF MULTIPLE MYELOMA PATIENTS DURING THE COVID-19 PANDEMIC
por: Luchinin, Alexander, et al.
Publicado: (2023)

PB2093: DIFFUSE LARGE B CELL LYMPHOMA IN THE ELDERLY
por: Abichou, G., et al.
Publicado: (2022)

PB2369: PERIPHERAL T CELL LYMPHOMA: EPIDEMIOLOGY AND CLINICAL CHARACTERISTICS
por: Charfi, Maha, et al.
Publicado: (2023)

PB2291: EFFICACY OF SPLENECTOMY IN SPLENIC MARGINAL ZONE LYMPHOMA
por: Yevstakhevych, Yuriy, et al.
Publicado: (2023)

PB2093: OVERALL SURVIVAL IN RELAPSED-REFRACTORY MYELOMA PATIENTS DEPENDS ON CIRCULATING PLASMA CELLS QUANTITATION
por: Parrinello, Nunziatina Laura, et al.
Publicado: (2023)

PB1837: ADDITION OF A THIRD, NON-TARGETED, AGENT TO CYTARABINE- AND ANTHRACYCLINE-BASED INDUCTION CHEMOTHERAPY FOR ACUTE MYELOBLASTIC LEUKEMIA INCREASES COMPLETE REMISSIONS AND TREATMENT-RELATED MORTALITY
por: Pereira, M., et al.
Publicado: (2022)

PB2155: B-CELL NON-HODGKIN’S LYMPHOMAS ASSOCIATED WITH AMYLOIDOSIS
por: Navrátilova, M., et al.
Publicado: (2022)

PB2064: RELAPSED/REFRACTORY HODGKIN LYMPHOMA PATIENTS TREATED WITH RADIOTHERAPY
por: Kallel, F., et al.
Publicado: (2022)

PB2062: EPIDEMIOLOGICAL, CLINICAL AND THERAPEUTIC FEATURES OF REFRACTORY HODGKIN’S LYMPHOMA.
por: Ben Sghaier, R., et al.
Publicado: (2022)

PB2161: CHARACTERISTICS OF AGGRESSIVE B-CELL LYMPHOMAS WITH MYC REARRANGEMENT
por: Ortuzar Pasalodos, A., et al.
Publicado: (2022)

PB2382: EFFECTS OF ANTIFASCIN COMPOUNDS AGAINST LYMPHOMA CELLS IN VITRO
por: María Hurtado López, Ana, et al.
Publicado: (2023)

PB2262: PROGNOSTIC FACTORS IN PATIENTS WITH RELAPSED/REFRACTORY HODGKINN LYMPHOMA
por: Zahra, Kmira, et al.
Publicado: (2023)

PB2284: EPIDEMIOLOGICAL, CLINICAL AND THERAPEUTIC ASPECT OF INDOLENT LYMPHOMAS IN TUNISIA
por: Charef, Ons, et al.
Publicado: (2023)

PB2057: REAL -WORLD OVERALL SURVIVAL OF MYELOFIBROSIS PATIENTS ON RUXOLITINIB – A 6 YEAR ANALYSIS IN ALBANIAN POPULATION
por: Perolla, A., et al.
Publicado: (2022)

PB1879: OVERALL SURVIVAL OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH IBRUTINIB IN ALBANIA (2018-2022)
por: Calliku, E., et al.
Publicado: (2022)

PB2162: INCREASED OXIDATIVE STRESS IN DIFFUSE LARGE B-CELL LYMPHOMA
por: Antic, D., et al.
Publicado: (2022)

PB2124: MYC EXPRESSION ANALYSIS AND PROGNOSIS VALUE IN TRANSFORMED FOLLICULAR LYMPHOMA
por: Liang, J., et al.
Publicado: (2022)

PB2158: EXPLORING THE BIOLOGICAL ROLE OF LILRA4 IN MANTLE CELL LYMPHOMA
por: Blum, M. K., et al.
Publicado: (2022)

PB2071: INTRALESIONAL RITUXIMAB IN THE TREATMENT OF PRIMARY CUTANEOUS B-CELL LYMPHOMA
por: Callejas Charavia, M., et al.
Publicado: (2022)

PB2283: COVID-19 (SARS-COV-2 INFECTION) IN LYMPHOMA PATIENTS
por: Tytorenko, I., et al.
Publicado: (2022)

PB2076: PEDIATRIC-TYPE FOLLICULAR LYMPHOMA - A NEW PARADIGM IN DIAGNOSIS?
por: Fonseca, L., et al.
Publicado: (2022)

PB2394: PTPRJ AS A ROBUST DIFFERENTIATING MARKER IN MANTLE CELL LYMPHOMA
por: Valentin Hansen, Simone, et al.
Publicado: (2023)

PB2256: EPIDEMIOLOGY AND OUTCOMES OF HODGKIN LYMPHOMA IN URUGUAY. A NATIONAL REGISTRY
por: Oliver, Carolina, et al.
Publicado: (2023)

PB2367: CLINICAL CHARACTERISTICS AND PROGNOSIS OF PATIENTS WITH NODAL PERIPHERAL T-CELL LYMPHOMA
por: Yahia, Noura Ben, et al.
Publicado: (2023)

PB2135: BURKITT LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX (BL-IPI): IS IT EFFICIENT ENOUGH IN ADULT BURKITT LYMPHOMA PATIENTS?
por: Sayinalp, B., et al.
Publicado: (2022)

PB2072: EFFICACY AND SIDE EFFECTS OF IBRUTINIB IN RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA
por: Basturk, A., et al.
Publicado: (2022)

PB2168: BRUSATOL INDUCES APOPTOSIS IN AGGRESSIVE LYMPHOMA CELLS IN VITRO AND SYNERGIZES WITH VENETOCLAX
por: Szmyra, M., et al.
Publicado: (2022)

PB2073: LACK OF AGREEMENT ON EVENT-FREE SURVIVAL DEFINITION IN MARGINAL ZONE LYMPHOMA
por: Bommier, C., et al.
Publicado: (2022)

PB2094: PRIMARY MEDIASTINAL B-CELL LYMPHOMA: EXPERIENCE OF THE HEMATOLOGY DEPARTMENT OF SFAX
por: Charfi, M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jsdu8kva9sp9251a1udi3dkfug